EB-003 is a non-hallucinogenic serotonin 5-HT1A and 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders and anxiety disorders. It is not a serotonin 5-HT2B receptor agonist. The drug is being developed by Enveric Biosciences. As of February 2025, it is in the preclinical research stage of development. Its chemical structure does not yet seem to have been disclosed, but it is said to be an indolethylamine (tryptamine). In addition, it has been patented, though the patent does not yet appear to have been published.